You are here Home Resources and guidance Sponsors Arrowhead Australia Pty Ltd Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type Designation or determination (2) Prescription medicine evaluation (1) Date 2025 (3) Search Sponsor content3 result(s) found, displaying 1 to 3 REDEMPLO Arrowhead Australia Pty Ltd Sep-2025 Prescription medicine evaluation Active ingredient: plozasiran sodium. Notice for plozasiran (Arrowhead Australia Pty Ltd) 20 June 2025 Designation or determination Priority review Notice for plozasiran (Arrowhead Australia Pty Ltd) 28 March 2025 Designation or determination Orphan drug
REDEMPLO Arrowhead Australia Pty Ltd Sep-2025 Prescription medicine evaluation Active ingredient: plozasiran sodium.
Notice for plozasiran (Arrowhead Australia Pty Ltd) 20 June 2025 Designation or determination Priority review
Notice for plozasiran (Arrowhead Australia Pty Ltd) 28 March 2025 Designation or determination Orphan drug